- Ad Age, Thursday, July 8, 2010 10:44 AM
Following a series of quality-related recalls and a plant shutdown, sales and market share for Johnson & Johnson's Tylenol are down by nearly two-thirds from a year ago, Jack Neff reports.
The bad publicity surrounding the recall is hurting other J&J brands such as Motrin, Benadryl and Zyrtec with "less equity and possibly less ability to bounce back from the troubles," Neff writes.
On the bright side, he points out, whatever PR difficulties J&J is having are being dwarfed by far-bigger corporate mistakes making headlines every day.
Read the whole story at Ad Age »